U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H39F2NO6
Molecular Weight 559.6424
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GW-870086

SMILES

C[C@]1([H])C[C@@]2([H])[C@]3([H])C[C@@]([H])(C4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)OCC#N)OC(=O)C5C(C)(C)C5(C)C)O)F)F

InChI

InChIKey=WUBKGTSFJSEIEM-NSHBDUGJSA-N
InChI=1S/C31H39F2NO6/c1-16-12-18-19-14-21(32)20-13-17(35)8-9-28(20,6)30(19,33)22(36)15-29(18,7)31(16,25(38)39-11-10-34)40-24(37)23-26(2,3)27(23,4)5/h8-9,13,16,18-19,21-23,36H,11-12,14-15H2,1-7H3/t16-,18+,19+,21+,22+,28+,29+,30+,31+/m1/s1

HIDE SMILES / InChI

Molecular Formula C31H39F2NO6
Molecular Weight 559.6424
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

GW-870086 (now known as GSK 870086) was developed by GlaxoSmithKline as a glucocorticoid receptor agonist. Repeat inhaled doses of GW-870086 was studied in phase II clinical trial in patients with asthma. In addition, phase II clinical trial was investigated to determine the efficacy of GW-870086 ream formulation in subjects with moderate to severe atopic dermatitis. However, the development of this drug appears to have been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial.
2013 Dec
Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile.
2013 Jul
Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X.
2013 Mar 1
Patents

Patents

Sample Use Guides

Dermatitis, Atopic: GW870086X cream formulation: GW870086 2.0%, GW870086 0.2% & Placebo each applied to a separate specific lesion for 21±2 days. Asthma: repeat inhaled doses of GW870086X
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:34:45 UTC 2021
Edited
by admin
on Sat Jun 26 00:34:45 UTC 2021
Record UNII
O891A2A3ZU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GW-870086
Common Name English
ANDROSTA-1,4-DIENE-17-CARBOXYLIC ACID, 6,9-DIFLUORO-11-HYDROXY-16-METHYL-3-OXO-17-(((2,2,3,3-TETRAMETHYLCYCLOPROPYL)CARBONYL)OXY)-, CYANOMETHYL ESTER, (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-
Systematic Name English
GW870086
Code English
GW870086X
Code English
Code System Code Type Description
DRUG BANK
DB12322
Created by admin on Sat Jun 26 00:34:45 UTC 2021 , Edited by admin on Sat Jun 26 00:34:45 UTC 2021
PRIMARY
CAS
827319-43-7
Created by admin on Sat Jun 26 00:34:45 UTC 2021 , Edited by admin on Sat Jun 26 00:34:45 UTC 2021
PRIMARY
FDA UNII
O891A2A3ZU
Created by admin on Sat Jun 26 00:34:45 UTC 2021 , Edited by admin on Sat Jun 26 00:34:45 UTC 2021
PRIMARY
PUBCHEM
11376392
Created by admin on Sat Jun 26 00:34:45 UTC 2021 , Edited by admin on Sat Jun 26 00:34:45 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY